第 1 到 38 筆結果,共 38 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | DE-RUI HUANG ; BIN-CHI LIAO ; Hsu, Wei-Hsun; CHING-YAO YANG ; YEN-TING LIN ; SHANG-GIN WU ; TZU-HSIU TSAI ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; ANN-LII CHENG ; YING-CHUN SHEN | Oncology | |||
2 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 20 | 13 | |
3 | 2022 | Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape | TSUNG-HAO LIU ; YING-CHUN SHEN ; ANN-LII CHENG | Journal of the Formosan Medical Association = Taiwan yi zhi | 3 | 2 | |
4 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
5 | 2021 | Evolution of systemic treatment for advanced hepatocellular carcinoma | Wu T.-C.; YING-CHUN SHEN ; ANN-LII CHENG | Kaohsiung Journal of Medical Sciences | 11 | 9 | |
6 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
7 | 2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 128 | 112 | |
8 | 2020 | Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma | Ying-Chun Shen ; CHIA-LANG HSU ; YUNG-MING JENG ; MING-CHIH HO ; CHENG-MAW HO ; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; REY-HENG HU ; ANN-LII CHENG | Journal of Hepatology | 35 | 35 | |
9 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
10 | 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
11 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
12 | 2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
13 | 2013 | erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5) | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 0 | 0 | |
14 | 2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 155 | 146 | |
15 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
16 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
17 | 2012 | Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 19 | 18 | |
18 | 2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
19 | 2012 | Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma | ANN-LII CHENG ; Ying-Chun Shen ; Zhu A.X. | Oncology | 39 | 41 | |
20 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
21 | 2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
22 | 2011 | Antiangiogenic strategies for the treatment of hepatocellular carcinoma | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Targeted Therapies for Hepatocellular Carcinoma | 0 | 0 | |
23 | 2010 | Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Contemporary Clinical Trials | 41 | 37 | |
24 | 2010 | Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach | Ying-Chun Shen ; CHIUN HSU ; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Journal of Hepatology | 124 | 113 | |
25 | 2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
26 | 2010 | Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | DA-LIANG OU ; Ying-Chun Shen ; SUNG-LIANG YU ; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; LIANG-IN LIN ; CHIUN HSU ; ANN-LII CHENG | Cancer Research | 70 | 69 | |
27 | 2010 | Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology | 62 | 54 | |
28 | 2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
29 | 2009 | Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia | CHING-HUNG LIN ; JAU-YU LIAU ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; Lee W.-C.; KUAN-TING KUO ; Ying-Chun Shen ; SUNG-HSIN KUO ; Lan C.; Liu J.M.; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 101 | 95 | |
30 | 2009 | Sorafenib for the treatment of hepatocellular carcinoma across geographic regions | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Expert review of Clinical Pharmacology | 10 | 0 | |
31 | 2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
32 | 2009 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | DA-LIANG OU ; Ying-Chun Shen ; JA-DER LIANG ; Liou J.-Y.; SUNG-LIANG YU ; Fan H.-H.; Wang D.-S.; YEN-SHEN LU ; CHIUN HSU ; ANN-LII CHENG | Clinical Cancer Research | 32 | 34 | |
33 | 2007 | Molecular targeted therapy for advanced hepatocellular carcinoma | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Targeted Oncology | 6 | 4 | |
34 | 2006 | Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; RUEY-LONG HONG ; Chang C.-J.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 67 | 51 | |
35 | 2005 | Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis | Ying-Chun Shen ; Chang C.-J.; CHIUN HSU ; Cheng C.-C.; Chiu C.-F.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 129 | 116 | |
36 | 2005 | Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung | KUN-HUEI YEH ; Shiou-Hwei Yeh ; Wan J.-P.; Ying-Chun Shen ; ANN-LII CHENG | Anti-Cancer Drugs | 4 | 3 | |
37 | 2004 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract | CHIUN HSU ; Ying-Chun Shen ; CHIH-HSIN YANG ; KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG | British Journal of Cancer | 42 | 40 | |
38 | 2004 | Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines | Ying-Chun Shen ; CHIUN HSU ; Chen J.-Y.; ANN-LII CHENG | British Journal of Cancer | 4 | 5 |